8-K: Moleculin Biotech Secures Georgia Approval for Pivotal AML Trial, Reports Strong Enrollment Progress

Moleculin Biotech, Inc. announced the approval of its pivotal Phase 2B/3 MIRACLE clinical trial for Annamycin in relapsed/refractory Acute Myeloid Leukemia in Georgia, alongside an update on enrollment and future site expansion plans.

Summary

• Moleculin Biotech, Inc. received approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for its Clinical Trial Application (CTA) to conduct the pivotal Phase 2B/3 MIRACLE study.
• The MIRACLE trial evaluates Annamycin in combination with cytarabine (AnnAraC) for adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy.
• This approval follows a recent CTA approval from the European Medicines Agency (EMA) in the European Union.
• Enrollment in Part A of the MIRACLE trial has reached seven subjects treated and one additional subject in screening at the first site in Ukraine.
• The Company expects to add 16 additional clinical sites in Europe and the US by the end of August, aiming for over 30 sites for Part A by year-end.
• The first patient in Georgia is expected to be treated by the end of August, if not sooner.
• Initial data readout on the first 45 subjects from Part A is anticipated in the second half of 2025.
• A second unblinding, involving 75 to 90 subjects, is expected in the first half of 2026.
• The trial utilizes an adaptive design, with Part A randomizing 75 to 90 subjects (1:1:1) to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for R/R AML and soft tissue sarcoma, and Orphan Drug Designation from the EMA for R/R AML.

Sentiment

Score: 7

Explanation: The approval of a pivotal trial in a new country and positive enrollment updates are significant advancements for a biotech company. However, the explicit mention of a need for significant additional financing without commitments introduces a notable risk, tempering the overall positive sentiment.

Positives

• Secured approval from RAMPA in Georgia for the pivotal Phase 2B/3 MIRACLE trial, expanding its global reach.
• Received recent EU approval from the European Medicines Agency (EMA), bolstering the trial's profile and ongoing enrollment efforts.
• Enrollment in Part A of MIRACLE has reached seven subjects treated and one additional subject in screening, demonstrating early recruitment success.
• Expects to add 16 additional clinical sites in Europe and the US by the end of August, building to over 30 sites for Part A by year-end, which should accelerate enrollment.
• Anticipated data readout of Part A remains on track for the second half of 2025, indicating adherence to timelines.
• The accelerated estimated timeline for unblinding is partly due to positive response from potential investigators regarding recruitment.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for R/R AML, and Orphan Drug Designation from the EMA for R/R AML, which can expedite development and provide market exclusivity.

Negatives

• Significant additional financing will be required to conduct clinical trials as described, and the Company has no commitments for this financing.
• EMA approval was granted under the condition that the Company present results of appropriate nonclinical GLP studies before initiating the Phase 3 portion (Part B) of the study.

Risks

• Significant additional financing will be required to conduct clinical trials as described, and the Company has no commitments for this financing, which could impact the ability to meet milestones.
• Expectations reflected in forward-looking statements may prove to be materially different from actual results.
• The Company's ability to reconcile the US and EU protocols with the FDA and EMA, respectively, is a factor.

Future Outlook

The Company remains focused on driving enrollment and advancing the MIRACLE program forward, with anticipated initial data readout on the first 45 subjects from Part A in the second half of 2025 and a second unblinding in the first half of 2026. The Company also needs to secure significant additional financing to conduct its clinical trials.

Management Comments

• "Building upon our recently announced CTA approval in the European Union (EU) from the European Medicines Agency (EMA), RAMPA approval of the MIRACLE trial protocol represents another important milestone and bolsters our ongoing enrollment efforts."
• "We expect to add 16 additional sites in Europe and the US to MIRACLE by the end of August. This will build to more than 30 sites by year-end for Part A of the MIRACLE."
• "Adding to this progress, our recruitment in Part A of MIRACLE has hit seven subjects treated and one in screening with just our first site in Ukraine."
• "All of this, importantly, supports our goal to report initial data on the first 45 subjects from Part A in the second half of 2025."
• "This early success in recruitment underscores the capability of our clinical sites, with the first ten screened subjects within just three months of site activation, and it showcases the commitment of ARENSIA Exploratory Medicines research clinic in Kyiv, Ukraine."
• "We are grateful for the continued international regulatory collaboration for this trial and believe it reflects the potential demand for Annamycin and the significant unmet need for better treatment options for R/R AML patients, especially venetoclax regimen failures where the outcomes from currently available therapies are considered dismal."
• "Our team remains focused on driving enrollment and advancing this important program forward."

Industry Context

The announcement relates to the development of a treatment for relapsed or refractory acute myeloid leukemia (R/R AML), a hard-to-treat cancer with a significant unmet medical need. Outcomes from currently available therapies for R/R AML patients, especially those with venetoclax regimen failures, are considered dismal. Annamycin is positioned as a next-generation anthracycline designed to overcome multidrug resistance and avoid cardiotoxicity common with existing treatments, potentially offering a much-needed alternative in this challenging therapeutic area.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the current findings against global benchmarks. It focuses on the company's internal progress and the general unmet medical need in R/R AML.

Stakeholder Impact

• Shareholders: Potential for increased value due to clinical trial progress and expansion, but also risk associated with the need for significant additional financing.
• Patients (R/R AML): Potential for a new, more effective treatment option for a disease with high unmet medical need and dismal outcomes with current therapies.
• Employees: Continued progress in the company's lead drug development program, potentially securing future growth.
• Regulatory Authorities: Ongoing collaboration and adherence to regulatory guidelines for clinical trial conduct and drug approval.

Next Steps

• Treat the first patient in Georgia by the end of August, if not sooner.
• Add 16 additional clinical sites in Europe and the US by the end of August.
• Build to more than 30 sites for Part A of MIRACLE by year-end.
• Report initial data on the first 45 subjects from Part A in the second half of 2025.
• Conduct the second unblinding (75 to 90 subjects) in the first half of 2026.
• Present results of appropriate nonclinical GLP studies to the EMA before initiating the Phase 3 portion (Part B) of the study.

Key Dates

Recommendation

Keywords

Moleculin Biotech, MBRX, Annamycin, AML, Acute Myeloid Leukemia, R/R AML, Relapsed Refractory AML, MIRACLE trial, Clinical Trial, Phase 3, Phase 2B/3, Oncology, Hematology, Drug Development, Biotechnology, Pharmaceuticals, Georgia, RAMPA, EMA, FDA, Orphan Drug, Fast Track, AnnAraC, Cytarabine, HiDAC